Chemotherapy in the primary treatment of cervical carcinoma

Serkies, Krystyna; Jassem, Jacek

doi:10.1016/j.critrevonc.2004.12.007

Cited by 14 publications

(12 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In surgical series including patients with FIGO stage I-IVA, an operability rate of 48-100% following primary chemotherapy was reported, without increased surgery-related morbidity. Pathologic complete responses were achieved in 9-27% of cases, and the incidence of lymph node metastases seemed to be markedly low (22) .…”

Section: Cervical Cancermentioning

confidence: 96%

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Basile

Angioli

Manci

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

The epidemiologic pattern of cancers in developing countries differs in many aspects from that of industrialized nations. Cancer natural history, microbiologic environment, patient's immune system, and drug availability may differ as well. Four of five new cases of cervical cancer and most of cervical cancer deaths occur in developing countries. Where chemoradiation and supportive care facilities are unavailable, it would be logical to consider an inexpensive effective drug. In locally advanced cases, neoadjuvant chemotherapy followed by surgery should be considered the treatment of choice. For ovarian cancer, it may be reasonable to maintain a secure supply of platinum and/or taxanes. For endometrial cancer, platinum compounds are proved active chemotherapic single agents. Oral medroxyprogesterone acetate (MPA) may represent a good chance for treating an advanced or recurrent disease. For vulvar/vaginal cancer, the role of chemotherapy alone is currently considered limited, and it is mostly used as palliative treatment in advanced or recurrent cases. Whenever possible, standard western chemotherapic regimens should be applied in developing countries as well. When standard therapies are unavailable, drugs of choice should be easily accessible, inexpensive, and effective. The most commonly used drugs are cisplatin, cyclophosphamide, and MPA.

show abstract

Section: Cervical Cancermentioning

confidence: 96%

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Basile

Angioli

Manci

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Improvements in the early detection of cervical cancers have substantially reduced the associated mortality rates over the past decades; however, in patients diagnosed with advanced cervical cancers, the mortality rates have remained unchanged over the past 25 years (27,28). Currently, advanced cervical cancer is treated with radiotherapy and cisplatin-based chemotherapy; nevertheless, unfortunately, most patients will eventually relapse, and improved treatment options for this type of malignancy are highly needed.…”

Section: Discussionmentioning

confidence: 99%

Targeting the Heat Shock Factor 1 by RNA Interference: A Potent Tool to Enhance Hyperthermochemotherapy Efficacy in Cervical Cancer

Rossi

Ciafrè²,

Balsamo³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

Carcinoma of the uterine cervix is one of the highest causes of mortality in female cancer patients worldwide, and improved treatment options for this type of malignancy are highly needed. Local hyperthermia has been successfully used in combination with systemic administration of cisplatin-based chemotherapy in phase I/II clinical studies. Heat-induced expression of cytoprotective and antiapoptotic heat shock proteins (HSP) is a known complication of hyperthermia, resulting in thermotolerance and chemoresistance and hindering the efficacy of the combination therapy. Heat shock transcription factor 1 (HSF1) is the master regulator of heatinduced HSP expression. In the present report, we used small interfering RNA (siRNA) to silence HSF1 and to examine the effect of HSF1 loss of function on the response to hyperthermia and cisplatin-based chemotherapy in HeLa cervical carcinoma. We have identified the 322-nucleotide to 340-nucleotide HSF1 sequence as an ideal target for siRNAmediated HSF1 silencing, have created a pSUPER-HSF1 vector able to potently suppress the HSF1 gene, and have generated for the first time human cancer cell lines with stable loss of HSF1 function. We report that, although it surprisingly does not affect cancer cell sensitivity to cisplatin or elevated temperatures up to 43°C when administered separately, loss of HSF1 function causes a dramatic increase in sensitivity to hyperthermochemotherapy, leading to massive (>95%) apoptosis of cancer cells. These findings indicate that disruption of HSF1-induced cytoprotection during hyperthermochemotherapy may represent a powerful strategy to selectively amplify the damage in cancer cells and identify HSF1 as a promising therapeutic target in cervical carcinoma. (Cancer Res 2006; 66(15): 7678-85)

show abstract

“…For example, systemic chemotherapy is typically the last or strictly concurrent option, after surgery and radiotherapy, for treatment of cervical cancer (3,4). In addition, systemic medications can lead to significant adverse side effects when high drug concentrations in the circulation are required to elicit a therapeutic response in the CV tract (5). To reduce side effects and achieve localized therapy, recent efforts have increasingly emphasized topical drug delivery methods, such as creams, hydrogels, and inserted devices, to deliver therapeutics to the apical side of the cervix epithelium (6)(7)(8)(9)(10)(11).…”

mentioning

confidence: 99%

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

Lai¹,

O’Hanlon

Harrold

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

900

1,012

View full text Add to dashboard Cite

Nanoparticles larger than the reported mesh-pore size range (10 -200 nm) in mucus have been thought to be much too large to undergo rapid diffusional transport through mucus barriers. However, large nanoparticles are preferred for higher drug encapsulation efficiency and the ability to provide sustained delivery of a wider array of drugs. We used high-speed multiple-particle tracking to quantify transport rates of individual polymeric particles of various sizes and surface chemistries in samples of fresh human cervicovaginal mucus. Both the mucin concentration and viscoelastic properties of these cervicovaginal samples are similar to those in many other human mucus secretions. Unexpectedly, we found that large nanoparticles, 500 and 200 nm in diameter, if coated with polyethylene glycol, diffused through mucus with an effective diffusion coefficient (D eff) only 4-and 6-fold lower than that for the same particles in water (at time scale ‫؍‬ 1 s). In contrast, for smaller but otherwise identical 100-nm coated particles, D eff was 200-fold lower in mucus than in water. For uncoated particles 100 -500 nm in diameter, D eff was 2,400-to 40,000-fold lower in mucus than in water. Much larger fractions of the 100-nm particles were immobilized or otherwise hindered by mucus than the large 200-to 500-nm particles. Thus, in contrast to the prevailing belief, these results demonstrate that large nanoparticles, if properly coated, can rapidly penetrate physiological human mucus, and they offer the prospect that large nanoparticles can be used for mucosal drug delivery. drug delivery ͉ mucosal tissues ͉ particle tracking ͉ PEG

show abstract

Chemotherapy in the primary treatment of cervical carcinoma

Cited by 14 publications

References 102 publications

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Targeting the Heat Shock Factor 1 by RNA Interference: A Potent Tool to Enhance Hyperthermochemotherapy Efficacy in Cervical Cancer

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

Contact Info

Product

Resources

About